OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Transposon Therapeutics

1 Projects | 1 Researchers | $4,995,519 Invested

2024

Transposon Therapeutics

Andrew Satlin, MD

A Phase 2 Clinical Trial to Study the Effect of TPN-101, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with Alzheimer's Disease

  • Funding Amount: $4,995,519
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuronal Degeneration
  • Status: Active